76 completed, 14 unknown, 6 recruiting, 6 withdrawn. 47 Phase 3, 27 Phase 4, 19 Phase 2, 9 Phase 1, 2 Early Phase 1.
Follow Vortioxetine: new trials by email Literature Review of Vortioxetine trials Research Report on Vortioxetine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Compare the Efficacy and Safety of KH607 Tablets Versus Vortioxetine Hydrobromide Tablets in Adult Patients With Major Depressive Disorder KH607 tablets, Vortioxetine Hydrobromide Tablets, Part B: KH607 - Major Depressive Disorder (MDD) | Phase 3 | Not yet recruiting | Chengdu Kanghong Pharmaceutical Group Co., Ltd. | 326 | 2026-07-01 | 2026-08-03 |
| Vortioxetine for Newly Diagnosed Glioblastoma Vortioxetine - Glioblastoma | Phase 2 | Recruiting | University of Zurich | 78 | 2026-06-24 | 2026-06-29 |
| RNA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipolar Depression (EDIT-ANDRE) Vortioxetine, Cariprazine (Augmentation Phase) - Unipolar Depression, Bipolar Depression | Phase 4 | Recruiting | Mayo Clinic | 120 | 2026-02-17 | 2026-06-22 |
| A Study of Vortioxetine in Japanese Pediatric Patients With Major Depressive Disorder Vortioxetine tablets, Placebo tablets - Major Depressive Disorder | Phase 3 | Recruiting | Takeda | 180 | 2025-10-01 | 2026-10-29 |
| Fortifying Healthy Behaviors, Optimizing Medical Therapies and Enhancing Cognitive Function in Older Adults-pilot Study Risk managment, Dasatinib, Quercetin (dietary supplement) - Aging, Cognitive Decline | Phase 2 | Completed | Washington University School of Medicine | 23 | 2025-07-28 | 2026-08-19 |
| Vortioxetine for the Treatment of Mood and Cognitive Symptoms in Frontotemporal Dementia Vortioxetine - Fronto-temporal Dementia, Fronto-temporal Lobar Dementia | Phase 2 | Recruiting | Johns Hopkins University | 50 | 2025-03-20 | 2026-03-09 |
| Vortioxetine for Depressive Symptoms and Freezing of Gait in Parkinson Disease Vortioxetine (tablet) - Parkinson Disease, Idiopathic, Freezing of Gait | Phase 4 | Not yet recruiting | Marianna Amboni | 40 | 2025-02-01 | 2025-02-06 |
| Postoperative Pain Management Following Laparoscopic Cholecystectomy Vortioxetine 20Mg Tab - Postoperative Pain | Phase 3 | Completed | Future University in Egypt | 86 | 2024-08-26 | 2026-09-21 |
| A Database Survey of Comparison The Risk of Haemorrhage Between Vortioxetine Tablet Treatment and Selective Serotonin Reuptake Inhibitor (SSRI) Treatment in Participants With Depression Vortioxetine Tablet, SSRI - Major Depressive Disorder | Completed | Takeda | 147777 | 2024-06-01 | 2025-03-03 | |
| Prediction of the Therapeutic Response in Depression Based on Neuro-computational Modeling Assessment of Motivation escitalopram, vortioxetine - Major Depressive Disorder | Not applicable | Recruiting | Centre Hospitalier St Anne | 136 | 2023-09-12 | 2024-07-10 |
| Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD) Fluoxetine, Sertraline, Vortioxetine - Depression, Sequestra | Phase 1 / Phase 2 | Recruiting | First Affiliated Hospital of Chongqing Medical University | 520 | 2023-02-20 | 2026-01-27 |
| Comparison of Vortioxetine Versus Other Antidepressants With Pregabalin Augmentation in Burning Mouth Syndrome Vortioxetine 20Mg Tab, Paroxetine 20 Mg Oral Tablet, Sertraline 50 MG - Burning Mouth Syndrome | Phase 3 | Unknown | Federico II University | 203 | 2023-01-01 | 2023-09-06 |
| Comparative Responses to 15 Different Antidepressants in Major Depressive Disorder Antidepressant - Major Depressive Disorder | Completed | Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital | 73336 | 2022-10-01 | 2023-08-18 | |
| Non-interventional, Retrospective Cohort Study to Explore Antidepressant Treatment in Korea Escitalopram, Paroxetine, Fluoxetine - Major Depression | Completed | Pfizer | 370212 | 2022-07-04 | 2024-12-09 | |
| Single Dose Oral Bioequivalence Study of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets Vortioxetine Hemihydrobromide Orally Disintegrating Tablets, Vortioxetine Hydrobromide Tablets - Major Depressive Disorder (MDD) | Phase 1 | Completed | Seasons Biotechnology (Taizhou) Co., Ltd. | 48 | 2022-06-27 | 2023-04-13 |
| Vortioxetine Adjunctive Treatment in Bipolar Depression Vortioxetine, valprote - Bipolar Depression | Phase 4 | Completed | First Affiliated Hospital of Zhejiang University | 131 | 2022-03-01 | 2023-09-14 |
| Vortioxetine as a Novel Anti-depressant With Improvement in Cognitive Abilities Vortioxetine, Venlafaxine - Major Depressive Disorder | Phase 3 | Unknown | Scotmann Pharmaceuticals | 500 | 2022-02-01 | 2021-11-18 |
| Cognitive Effects of Adjuvant Vortioxetine in Early Schizophrenia Vortioxetine, Usual Antipsychotic Treatment - Cognitive Impairment With Primary Psychotic Disorder, Negative Symptoms With Primary Psychotic Disorder | Phase 2 / Phase 3 | Unknown | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | 37 | 2022-01-20 | 2024-02-26 |
| Vortioxetine for Post-COVID-19 Condition Vortioxetine, Placebo - Post-COVID-19 Condition, Post-COVID-19 Syndrome | Phase 2 | Completed | Brain and Cognition Discovery Foundation | 149 | 2021-09-16 | 2025-01-16 |
| Vortioxetine to Prevent Return of Symptoms in Children With Depression Vortioxetine, Placebo - Depression | Phase 3 | Terminated | H. Lundbeck A/S | 35 | 2021-08-10 | 2023-01-05 |
Showing 20 of 107. Sign in to see all of them.
Depressive Disorder, Major (64) · Depression (30) · Depressive Disorder (10) · Anxiety Disorders (8) · Mood Disorders (6) · Cognitive Dysfunction (5) · Generalized Anxiety Disorder (5) · Bipolar Disorder (4) · Cognition Disorders (2) · Diabetes Mellitus, Type 2 (2) · Mental Disorders (2) · Parkinson Disease (2) · Alcoholism (1) · Attention Deficit Disorder with Hyperactivity (1) · Behavioral Symptoms (1)
H. Lundbeck A/S (34) · Takeda (26) · Brain and Cognition Discovery Foundation (2) · Johns Hopkins University (2) · Massachusetts General Hospital (2) · University of Miami (2) · Washington University School of Medicine (2) · Alen Greš (1) · Azienda Ospedaliera Universitaria Integrata Verona (1) · Central South University (1) · Centre Hospitalier St Anne (1) · Chengdu Kanghong Pharmaceutical Group Co., Ltd. (1) · Federico II University (1) · First Affiliated Hospital of Chongqing Medical University (1) · First Affiliated Hospital of Zhejiang University (1)
United States (38) · Estonia (13) · France (13) · Germany (13) · Poland (12) · Russia (12) · Italy (11) · Latvia (11) · South Korea (11) · Ukraine (11) · Canada (10) · Spain (9) · Serbia (8) · Bulgaria (7) · Finland (7)
Eric Lenze, MD (2) · Albert KK Chung, MBBS(HK) (1) · Andrew Nierenberg, M.D. (1) · Aysegul Ozerdem, MD, PhD (1) · Benedicto Crespo Facorro, Professor (1) · Chong Guan Ng (1) · Christoph U Correll, MD (1) · Christopher Morrow, MD (1) · Deniz Ceylan, MD, PhD (1)
PMID 27780334, PMID 31818787, PMID 36708956, PMID 30439678, PMID 29081307, PMID 29160598, PMID 31087825, PMID 32242018, PMID 21767441, PMID 22209361, PMID 22475889, PMID 22495621, PMID 22572889, PMID 22898365, PMID 22901736, PMID 22963932, PMID 22978748, PMID 23252878, PMID 24257717, PMID 24341301, PMID 24424707, PMID 24787143, PMID 25087600, PMID 25575488, PMID 25650503, PMID 26035185, PMID 26035186, PMID 28213121, PMID 28858412, PMID 29035574, PMID 29235884, PMID 29546401, PMID 29554497, PMID 29689693, PMID 29760763, PMID 30766492, PMID 30802419, PMID 31010445, PMID 31094901, PMID 31404802, PMID 31422713, PMID 31552551, PMID 31930057, PMID 31990207, PMID 32212856, PMID 32384884, PMID 32670103, PMID 32746941, PMID 32784346, PMID 33587394
2008 (8), 2014 (3), 2018 (3), 2015 (2), 2009 (1), 2016 (1), K23AG088248 (1)